-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Downgrades Inozyme Pharma to Hold, Lowers Price Target to $4

Benzinga·05/16/2025 20:10:08
Listen to the news
Jefferies analyst Ryan Deschner downgrades Inozyme Pharma (NASDAQ:INZY) from Buy to Hold and lowers the price target from $15 to $4.